iOncologi, Inc. Acquires TargImmune Therapeutics To Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors

UF startup iOncologi, Inc., a clinical-stage biopharmaceutical company focused on advancing immunotherapy platform technologies, announced the acquisition of TargImmune Therapeutics, a biotechnology company specializing in novel tumor targeted immunotherapies. This strategic acquisition significantly enhances iOncologi’s capabilities in developing cutting-edge immunotherapies for solid tumors.

As part of the transaction, iOncologi, Inc. and TargImmune Therapeutics executed a share purchase agreement, resulting in iOncologi acquiring at least 99% of TargImmune’s shares, warrants, and options. Following the acquisition, TargImmune will continue to operate in Basel, Switzerland, as a wholly owned subsidiary of iOncologi, Inc. This structure ensures the seamless continuation of TargImmune’s research into novel tumor-targeted RNA therapies while benefiting from iOncologi’s expanded resources and strategic vision.

Read more about iOncologi, Inc. Acquires TargImmune Therapeutics To Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors.